RETINOID-ASSOCIATED RECEPTOR REGULATORS

摘要

A pharmaceutical composition of the invention which is a retinoid-related receptor function regulating agent comprising a 1,3-azole derivative represented by formula (I): <CHEM> wherein R<1> is an aromatic hydrocarbon group or an aromatic heterocyclic group, each of which may be substituted; R<2> is hydrogen or an optionally substituted hydrocarbon group; X is O, S or a group represented by the formula: -NR<4>- wherein R<4> is hydrogen or an optionally substituted alkyl group; A is an aromatic hydrocarbon group or an aromatic heterocyclic group, each of which may be substituted; R<3> is a group represented by the formula: -OR<5> wherein R<5> is hydrogen or an optionally substituted hydrocarbon group, or -NR<6>R<7> wherein R<6> and R<7> are same or different and each is hydrogen or an optionally substituted hydrocarbon group, or R<6> and R<7> may be taken together with an adjacent nitrogen atom to form a ring, provided that compounds represented by the formulae: <CHEM> <CHEM> are excluded, or its salt, is low in toxicity, and can be employed, for instance, as an agent for preventing or treating diabetes (e.g., insulin-dependent diabetes, non-insulin-dependent diabetes, gestational diabetes), an agent for preventing or treating hyperlipidemia (e.g., hypertriglyceridemia, hypercholesterolemia, hypo-HDL-cholesterolemia), an insulin sensitivity enhancing agent, an insulin resistance improving agent, an agent for preventing or treating impaired glucose tolerance (IGT), and an agent for preventing transition from impaired glucose tolerance to diabetes. Further, a pharmaceutical composition of the invention can be used, for instance, as an agent for preventing or treating diabetic complications (e.g., neuropathy, nephropathy, retinopathy, cataract, macroangiopathy, osteopenia), obesity, osteoporosis, cachexia (e.g., carcinomatous cachexia, tuberculous cachexia, diabetic cachexia, hemopathic cachexia, endocrinopathic cachexia, infectious cachexia or cachexia induced by acquired immunodeficiency syndrome), fatty liver, hypertension, polycystic ovary syndrome, renal diseases (e.g., diabetic nephropathy, glomerular nephritis, glomerulosclerosis, nephrotic syndrome, hypertensive nephrosclerosis, terminal renal disorder), muscular dystrophy, myocardiac infarction, angina pectoris, cerebral infarction, insulin resistant syndrome, syndrome X, hyperinsulinemia-induced sensory disorder, tumor (e.g., leukemia, breast cancer, prostate cancer, skin cancer), arteriosclerosis (e.g., atherosclerosis) and as a pharmaceutical for controlling appetite or food intake.